XSXinli Song

Xinli Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinli Song has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Xu

    School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China

    2 shared publications
  • Shiyun Wang

    School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China

    2 shared publications
  • Yanli Cai

    School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, China

    2 shared publications
  • Changfu Yang

    College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China

    1 shared publication
  • Chenghao Tao

    College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China

    1 shared publication
  • Daobin Yang

    The Second Affiliated Hospital of Guizhou, University of Traditional Chinese Medicine, Guiyang, 550025, China

    1 shared publication

Latest Publications

  • Open Access

    Optimization of Xiaoer Lingyin granule formulation using single-factor and response surface methodology

    by Yanru Liu, Taoyang Cai, S. K. Kot-Cheung, Xinli Song, Feixiong Chen

    The study aimed to develop and optimize Xiaoer Lingyin granules (XLGs), a pediatric Chinese medicine formulation for acute pharyngitis, by integrating single-factor experiments, multi-index quality evaluation, and response surface methodology (RSM).

  • Acupoint-administered sinapine thiocyanate-loaded dissolvable microneedles for bronchial asthma: dose–response relationship and PI3K/AKT signaling pathway-based mechanism

    by Nan Wang, Jianan Shi, Shiyun Wang, Yanli Cai, Zhuxin Liu, Taowei Song, Jian Xu, Daobin Yang, Jianfeng Zhang, Zhongfen Chen, et al.

    Bronchial asthma (BA) is a chronic inflammatory airway disease for which conventional drug delivery routes show limited therapeutic efficacy. Herbal acupoint application offers targeted therapeutic benefits by combining pharmacological effects with specific acupoint stimulation; however, conventional patches are limited by poor sustained release and low patient compliance. Sinapine thiocyanate, a natural alkaloid with anti-inflammatory properties, has potential for asthma treatment, yet its poor bioavailability hinders its therapeutic application. To address these gaps, we developed sinapine thiocyanate‑loaded dissolvable microneedles (ST‑DMN) using polyvinylpyrrolidone K30 (PVP‑K30) and chondroitin sulfate (CS) as matrix materials, and polyvinyl alcohol (PVA) as the backing layer, designed for acupoint administration to achieve sustained drug release and improve therapeutic outcomes. ST-DMN patches with drug loadings ranging from 0.25 to 2.0 mg/patch were prepared, and a dose-response relationship was established in a rat model of BA to identify the optimal drug loading. The results demonstrated that ST-DMN at 1.5 and 2.0 mg/patch significantly improved the behavioral status of asthmatic rats, increased immune organ coefficients, and reduced the expression of IgE, TNF-α, and IL-1β. Based on a comprehensive assessment of efficacy and safety, 1.5 mg/patch was selected as the optimal dose. Network pharmacology analysis predicted that the PI3K/AKT signaling pathway was highly relevant to the anti-asthmatic effects of sinapine thiocyanate. Subsequent validation in animal models confirmed that the optimal dose of ST-DMN effectively ameliorated lung tissue pathology and reduced inflammatory cell infiltration. Furthermore, ST-DMN treatment significantly decreased the expression levels of key inflammatory factors and inhibited PI3K and AKT phosphorylation. The current findings suggest that ST-DMN at 1.5 mg/patch exerts therapeutic effects against BA through acupoint administration, likely by modulating the PI3K/AKT signaling pathway and suppressing inflammatory responses.

  • Brucine-loaded hydrogel microneedles for sustained anti-inflammatory therapy in rheumatoid arthritis: programmable drug release and detachable design

    by Shuqi Qian, Kailong Wan, Jian Xu, Xueming Yao, Tiantian Li, Li Chen, Li Shen, Shiyun Wang, Yanli Cai, Xinli Song

    This study aimed to develop a brucine (Bru) hydrogel-forming microneedle (Bru-HFM) delivery system that could achieve long-term, programmed drug release, through adjusting degree of cross-linking in polyvinyl alcohol (PVA)/carbomer 934P (CP) hydrogel. A one-way orthogonal experiment and a Franz diffusion cell were employed to optimize the preparation process. The resulting Bru-HFM exhibited favorable appearance, mechanical strength, and swelling properties. The drug release performance of the different drug-carrying sites of HFMs was compared. The results illustrated that in vivo drug release rate over 144 h was significantly higher in the needle body-carrying group (95.32%) than in the whole-microneedle (51.85%) and back-lining groups (57.39%). The amount of residue in the back-lining group was obvious, in line with expectations. The burst release rate of 78.81% could meet the high-dose demand during the acute phase of inflammation, whereas continuous release through the cross-linking network over 48-144 h achieved a total release rate of 95.32%. This covered the maintenance phase of chronic inflammation treatment, and the microneedles remained structurally intact at the end of drug release, permitting their detachable. The general pharmacodynamic evaluation results demonstrated that the pathological state of the ankle joints of rats with collagen-induced arthritis was significantly improved in the needle body-carrying group, which also exhibited significantly reduced serum levels of IL-6, IL-17, and TNF-α (all P < 0.05), indicating a significant therapeutic effect on rheumatoid arthritis. This study provides a new strategy and theoretical basis for designing HFMs for programmed drug release and inflammatory disease treatment.


  • Enhanced efficacy of brucine dissolving-microneedles as a targeted delivery system in rheumatoid arthritis treatment: a comprehensive pharmacokinetic-pharmacodynamic analysis

    by Yunxia Wang, Changfu Yang, Wen Liu, Yongping Zhang, Qun Wang, Huanhuan Cheng, Jianan Shi, Xiaoshuang Yang, Shenglei Yang, Xueming Yao, et al.

    Our previous studies have shown the therapeutic efficacy of brucine dissolving-microneedles (Bru-DMNs) in treating rheumatoid arthritis (RA). Bru delivered via the DMNs can bypass some of the issues related to oral and systemic delivery, including extensive enzymatic activity, liver metabolism and in the case of systemic delivery via hypodermic needles, pain resulting from injections and needle stick injury. However, the underlying mechanism of Bru-DMNs against RA has not been investigated in depth at the pharmacokinetic-pharmacodynamic (PK-PD) level. In this study, a microdialysis-based method combined with ultra-performance liquid chromatography-tandem mass spectrometry was developed for the simultaneous and continuous sampling and quantitative analysis of blood and joint cavities in fully awake RA rats. The acquired data were analyzed by the PK-PD analysis method. Bru delivered via microneedles showed enhanced distribution and prolonged retention in the joint cavity compared to its administration in blood. The correlation between the effect of Bru and its concentration at the action site was indirect. In this study, we explored the mechanism of Bru-DMNs against RA and established a visualization method to express the PK-PD relationship of Bru-DMNs against RA. This study provides insights into the mechanism of action of drugs with potential side effects administered transdermally for RA treatment. Graphical Abstract


  • Flexible two-layer dissolving and safing microneedle transdermal of neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis

    by Wendong Yao, Chenghao Tao, Jiafeng Zou, Hongyue Zheng, Jingjing Zhu, Zhihong Zhu, Jiazhen Zhu, Lin Liu, Fanzhu Li, Xinli Song